Online inquiry

IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13077MR)

This product GTTS-WQ13077MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MADCAM1 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_130760.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8174
UniProt ID Q13477
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13077MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9220MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ13207MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ2980MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ479MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ4890MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ7588MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ14490MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ11852MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW